ORBIMED ADVISORS LLC
Long book
$4.42B
Q1 2026
Positions
105
Top-10 weight
44%
concentration
Last quarter
+17.4%
SPY +14.8%
Turnover
34%
of book per quarter
Strategy in plain words
auto-generated from filingsORBIMED ADVISORS LLC is a diversified fundamental manager, specialised in healthcare (97% of the long book), running a $4.42B US long book across 105 positions.
The portfolio is moderately concentrated (top 10 ≈ 44% of the book). The portfolio is actively managed, with meaningful quarterly turnover. Current anchor positions: EDGEWISE THERAPEUTICS INC, ENLIVEN THERAPEUTICS INC, ELI LILLY & CO, SINOVAC BIOTECH LTD, BOSTON SCIENTIFIC CORP.
Over the last 9 quarters its long book ran on average 1.8pp per quarter behind the S&P 500, beating the index in 4 of 9 quarters. We rate its filings as signal-bearing: position changes reflect genuine views.
Implied long-book return vs S&P 500
methodology: positions priced quarterly, no shorts/options Fund long book S&P 500
Q1 2024
-2.8%
Q2 2024
+9.7%
Q3 2024
-10.4%
Q4 2024
-10.4%
Q1 2025
+2.5%
Q2 2025
+1.1%
Q3 2025
+18.5%
Q4 2025
-1.0%
Q1 2026
+17.4%
Sector allocation
Healthcare 97%
Technology 1%
Financials 1%
Other 1%
Materials 0%
Long book by quarter
What does ORBIMED ADVISORS own?
Q1 2026 13F| Company | Sector | Shares | Value | % of book | Change |
|---|---|---|---|---|---|
| EWTX EDGEWISE THERAPEUTICS INC | Healthcare | 15.5M | $488.8M | 11.1% | Held |
| ELVN ENLIVEN THERAPEUTICS INC | Healthcare | 8.0M | $312.0M | 7.1% | Held |
| LLY ELI LILLY & CO | Healthcare | 236.8K | $217.8M | 4.9% | -21.4% |
| SVA SINOVAC BIOTECH LTD | Healthcare | 2.7M | $184.5M | 4.2% | Held |
| BSX BOSTON SCIENTIFIC CORP | Healthcare | 2.4M | $149.5M | 3.4% | -1.5% |
| SION SIONNA THERAPEUTICS INC | Healthcare | 3.5M | $141.5M | 3.2% | -0.9% |
| AZN ASTRAZENECA PLC | Healthcare | 670.2K | $132.2M | 3.0% | New |
| MBX MBX BIOSCIENCES INC | Healthcare | 3.6M | $108.6M | 2.5% | -7.6% |
| CRVS CORVUS PHARMACEUTICALS INC | Healthcare | 7.2M | $104.8M | 2.4% | Held |
| EW EDWARDS LIFESCIENCES CORP | Healthcare | 1.2M | $98.5M | 2.2% | -33.2% |
| ISRG INTUITIVE SURGICAL INC | Healthcare | 208.7K | $96.2M | 2.2% | -20.8% |
| CMPX COMPASS THERAPEUTICS INC | Healthcare | 15.2M | $80.5M | 1.8% | Held |
| MRK MERCK & CO. INC. | Healthcare | 663.4K | $79.8M | 1.8% | New |
| AVBP ARRIVENT BIOPHARMA INC | Healthcare | 3.0M | $69.8M | 1.6% | Held |
| IRON DISC MEDICINE INC | Healthcare | 1.1M | $68.3M | 1.5% | Held |
| SPRY ARS PHARMACEUTICALS INC | Healthcare | 8.3M | $66.6M | 1.5% | Held |
| CGON CG ONCOLOGY INC | Healthcare | 948.3K | $64.2M | 1.5% | -37.5% |
| XENE XENON PHARMACEUTICALS INC | Healthcare | 1.1M | $61.6M | 1.4% | +137.0% |
| SYK STRYKER CORP | Healthcare | 182.5K | $60.0M | 1.4% | -43.8% |
| BMY BRISTOL-MYERS SQUIBB CO | Healthcare | 925.0K | $56.1M | 1.3% | +19.4% |
| MLYS MINERALYS THERAPEUTICS INC | Healthcare | 2.1M | $55.6M | 1.3% | +109.4% |
| PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 172.5K | $55.6M | 1.3% | +82.5% |
| PFE PFIZER INC | Healthcare | 1.9M | $54.7M | 1.2% | +17.8% |
| DYN DYNE THERAPEUTICS INC | Healthcare | 2.9M | $52.9M | 1.2% | +32.5% |
| NTRA NATERA INC | Healthcare | 262.0K | $52.4M | 1.2% | -28.4% |
| UPB UPSTREAM BIO INC | Healthcare | 5.7M | $51.2M | 1.2% | Held |
| DHR DANAHER CORP | Technology | 265.8K | $50.4M | 1.1% | -11.3% |
| CAI CARIS LIFE SCIENCES INC | Healthcare | 2.8M | $50.2M | 1.1% | -9.9% |
| STTK SHATTUCK LABS INC | Healthcare | 6.3M | $40.5M | 0.9% | Held |
| GH GUARDANT HEALTH INC | Healthcare | 435.2K | $40.2M | 0.9% | New |
| ALNY ALNYLAM PHARMACEUTICALS INC | Healthcare | 119.0K | $39.4M | 0.9% | -58.8% |
| PRLD PRELUDE THERAPEUTICS INC | Healthcare | 10.9M | $37.3M | 0.8% | Held |
| CRNX CRINETICS PHARMACEUTICALS IN | Healthcare | 999.0K | $36.3M | 0.8% | Held |
| AXSM AXSOME THERAPEUTICS INC | Healthcare | 213.9K | $36.2M | 0.8% | -15.5% |
| QURE UNIQURE NV | Healthcare | 2.1M | $34.9M | 0.8% | +189.7% |
| ORIC ORIC PHARMACEUTICALS INC | Healthcare | 2.7M | $34.1M | 0.8% | -26.0% |
| ELV ELEVANCE HEALTH INC | Financials | 114.7K | $33.6M | 0.8% | +15.7% |
| RLMD RELMADA THERAPEUTICS INC | Healthcare | 4.7M | $32.8M | 0.7% | +80.6% |
| FBRX FORTE BIOSCIENCES INC | Healthcare | 1.2M | $31.0M | 0.7% | Held |
| TRVI TREVI THERAPEUTICS INC | Healthcare | 2.5M | $29.3M | 0.7% | -23.1% |
| ESPR ESPERION THERAPEUTICS INC | Healthcare | 10.6M | $29.0M | 0.7% | +77.2% |
| NPCE NEUROPACE INC | Healthcare | 2.1M | $27.6M | 0.6% | -12.9% |
| RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 314.1K | $27.3M | 0.6% | +31.0% |
| TMO THERMO FISHER SCIENTIFIC INC | Other | 46.5K | $22.9M | 0.5% | Held |
| SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 962.3K | $22.5M | 0.5% | New |
| BTSG BRIGHTSPRING HEALTH SERVICES | Healthcare | 497.8K | $21.2M | 0.5% | +1.9% |
| LXEO LEXEO THERAPEUTICS INC | Healthcare | 3.6M | $20.7M | 0.5% | +69.5% |
| STRO SUTRO BIOPHARMA INC | Healthcare | 801.1K | $20.0M | 0.5% | New |
| NKTR NEKTAR THERAPEUTICS | Healthcare | 275.0K | $19.8M | 0.4% | New |
| HELP CYBIN INC | Healthcare | 3.8M | $18.4M | 0.4% | -0.2% |
13F filing history
| Period | Form | Filed | Entries | Reported value | Flags | Source |
|---|---|---|---|---|---|---|
| Q1 2026 | 13F-HR | May 15, 2026 | 114 | $5.05B | canonical | SEC ↗ |
| Q4 2025 | 13F-HR | Feb 17, 2026 | 108 | $4.90B | canonical | SEC ↗ |
| Q3 2025 | 13F-HR | Nov 14, 2025 | 110 | $4.26B | canonical | SEC ↗ |
| Q2 2025 | 13F-HR | Aug 14, 2025 | 103 | $4.00B | canonical | SEC ↗ |
| Q1 2025 | 13F-HR | May 15, 2025 | 111 | $4.19B | canonical | SEC ↗ |
| Q4 2024 | 13F-HR | Feb 14, 2025 | 119 | $4.86B | canonical | SEC ↗ |
| Q3 2024 | 13F-HR | Nov 14, 2024 | 119 | $5.50B | canonical | SEC ↗ |
| Q2 2024 | 13F-HR | Aug 14, 2024 | 115 | $5.06B | canonical | SEC ↗ |
| Q1 2024 | 13F-HR | May 15, 2024 | 115 | $5.46B | canonical | SEC ↗ |